OnKure Therapeutics (NASDAQ:OKUR) Releases Quarterly Earnings Results, Beats Estimates By $0.16 EPS

OnKure Therapeutics (NASDAQ:OKUR) announced its quarterly earnings results on Thursday. The company reported ($0.99) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.16, FiscalAI reports.

OnKure Therapeutics Trading Down 0.3%

Shares of NASDAQ:OKUR traded down $0.01 during trading on Thursday, hitting $3.52. 96,864 shares of the company’s stock traded hands, compared to its average volume of 113,119. The company has a 50-day moving average price of $2.81 and a 200-day moving average price of $2.86. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $5.28. The company has a market cap of $47.69 million, a price-to-earnings ratio of -0.73 and a beta of 0.45.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new stake in shares of OnKure Therapeutics during the second quarter worth $25,000. Rangeley Capital LLC acquired a new position in OnKure Therapeutics in the 2nd quarter worth $71,000. Shay Capital LLC boosted its stake in OnKure Therapeutics by 417.8% in the 2nd quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock worth $1,869,000 after purchasing an additional 631,008 shares during the period. Rosalind Advisors Inc. acquired a new stake in shares of OnKure Therapeutics in the 4th quarter valued at about $2,118,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of OnKure Therapeutics by 40.7% in the fourth quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock valued at $717,000 after purchasing an additional 71,600 shares in the last quarter. Institutional investors own 90.98% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $34.00.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.